Edgestream Partners L.P. Takes Position in HealthEquity, Inc. (NASDAQ:HQY)

Edgestream Partners L.P. purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,008 shares of the company's stock, valued at approximately $1,228,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in HQY. International Assets Investment Management LLC acquired a new position in shares of HealthEquity during the 2nd quarter valued at $35,000. Paladin Wealth LLC purchased a new position in shares of HealthEquity in the third quarter worth approximately $39,000. GAMMA Investing LLC raised its holdings in shares of HealthEquity by 114.8% during the second quarter. GAMMA Investing LLC now owns 595 shares of the company's stock valued at $51,000 after acquiring an additional 318 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity in the 2nd quarter valued at approximately $73,000. Finally, 1620 Investment Advisors Inc. purchased a new stake in shares of HealthEquity in the 3rd quarter valued at approximately $112,000. Institutional investors own 99.55% of the company's stock.

HealthEquity Stock Performance

Shares of NASDAQ:HQY traded down $2.16 during trading on Thursday, reaching $100.85. 529,445 shares of the stock were exchanged, compared to its average volume of 623,586. The firm has a market cap of $8.81 billion, a PE ratio of 85.83, a PEG ratio of 1.59 and a beta of 0.55. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 12 month low of $62.10 and a 12 month high of $105.82. The stock has a 50-day moving average price of $91.57 and a 200-day moving average price of $83.31.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. Research analysts expect that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Frank Corvino sold 1,039 shares of the business's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the transaction, the director now owns 3,784 shares of the company's stock, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company's stock, valued at $4,540,582.62. This trade represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock valued at $884,517 in the last three months. Corporate insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HQY. Bank of America increased their price target on shares of HealthEquity from $100.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. The Goldman Sachs Group began coverage on HealthEquity in a report on Friday, November 15th. They set a "neutral" rating and a $108.00 target price on the stock. Barrington Research upped their price target on HealthEquity from $105.00 to $120.00 and gave the stock an "outperform" rating in a research note on Monday. Deutsche Bank Aktiengesellschaft raised their price objective on HealthEquity from $102.00 to $103.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $105.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $109.64.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.